2003 Testimonials Trials Vaccine 
Drug & Device Law
FEBRUARY 20, 2023
For several decades – starting with plaintiffs’ pre-Vaccine Act attacks on vaccine designs – courts have addressed FDA approval as a component of “feasibility” in states that impose this limitation on design defect claims. Or does it suffice that a vaccine design has been approved in other countries? In Bruesewitz v.
Drug & Device Law
MARCH 4, 2024
Plaintiffs will not be heard to argue that they “could have shored up their cases by other means had they known their expert testimony would be found inadmissible.” His inability to produce admissible expert testimony is due to his own actions, namely the failure of his proposed experts to test their alternatives. Weisgram v.
Expert insights. Personalized for you.
59 
Let's personalize your content